I posted this response in the comments section of Adams article. It has not shown up.
"But Probuphine will be a "first-line" treatment. "Second-line" means that the drug can only be
prescribed if the "first-line" treatment fails or the patient relapses. Probuphine will compete
against the only other viable alternative, Suboxone, So it will be a "first-line". There are no
generics on the market. If you have any information that the FDA will approve Probuphine
for "second-line" use only, please cite your source, if not, kindly acknowledge that what you
wrote is a complete fabrication.
The growing concern is the diversion and abuse of the oral pill form of buprenorphine, so
much so, that Reckitt Benckiser pulled the pill and is only marketing the film strip.
Probuphine addresses the abuse and diversion concerns better than the film strip. So, it's
superior to the $1.5 billion product on the market now.
According to "Addiction Treatment Magazine": Experts estimate that nearly 750,000
Americans are on medication for opioid addiction. The approval of Probuphine would allow
the estimated 2.3 million opioid addicts in the U.S. an alternative medication that may be
more effective for their lifestyle."
Woodside Capital and Keelin Reeds market analysis shows that Probuphine should be able to
generate up to $500 million in sales.
Doesn't the patient have a choice in his/her treatment? Or do the doctors decide which drug to prescribe without any consultation with the patient? It seems to me the doc would ask the patient which type of treatment they prefer, but then I'm not a Dr. just a guy holding a little sack of stocks asking questions.